Seagen Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1998-01-01
- Employees
- 3.2K
- Market Cap
- -
- Website
- http://www.seagen.com
A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML
- First Posted Date
- 2014-12-29
- Last Posted Date
- 2018-05-09
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 116
- Registration Number
- NCT02326584
- Locations
- 🇺🇸
James Cancer Hospital / Ohio State University, Columbus, Ohio, United States
🇺🇸Cardinal Bernardin Cancer Center / Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸Charles A. Sammons Cancer Center / Baylor University Medical Center, Dallas, Texas, United States
Safety Study of SGN-CD70A in Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2014-08-15
- Last Posted Date
- 2018-04-19
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT02216890
- Locations
- 🇺🇸
Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸James P. Wilmot Cancer Center / University of Rochester Medical Center, Rochester, New York, United States
A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-12-31
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT02025192
- Locations
- 🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸Northwest Medical Specialties, Tacoma, Washington, United States
🇺🇸Providence Cancer Center, Portland, Oregon, United States
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
- First Posted Date
- 2013-12-05
- Last Posted Date
- 2021-12-29
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 195
- Registration Number
- NCT02001623
- Locations
- 🇧🇪
CHU UCL Namur - Sainte Elisabeth, Namur, Belgium
🇬🇧University College London Hospitals, London, England, United Kingdom
🇧🇪Universitair Ziekenhuis Antwerpen, Edegem, Antwerpen, Belgium
A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-11-14
- Last Posted Date
- 2020-09-21
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 57
- Registration Number
- NCT01983501
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇨🇦Hospital de la Cite-de-la-Sante, Laval, Quebec, Canada
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
A Safety Study of SGN-LIV1A in Breast Cancer Patients
- First Posted Date
- 2013-10-25
- Last Posted Date
- 2023-03-07
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 290
- Registration Number
- NCT01969643
- Locations
- 🇺🇸
University of Maryland, Baltimore, Maryland, United States
🇺🇸Northwest Medical Specialties, Puyallup, Washington, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)
- Conditions
- Interventions
- First Posted Date
- 2013-08-20
- Last Posted Date
- 2018-06-21
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 87
- Registration Number
- NCT01925612
- Locations
- 🇺🇸
Mid Ohio Oncology/Hematology Inc, Columbus, Ohio, United States
🇺🇸Texas Oncology - Baylor Sammons Cancer Center, Dallas, Texas, United States
🇺🇸Johns Hopkins Medical Center, Baltimore, Maryland, United States
A Safety Study of SGN-CD33A in AML Patients
- Conditions
- Interventions
- First Posted Date
- 2013-07-18
- Last Posted Date
- 2018-01-05
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 195
- Registration Number
- NCT01902329
- Locations
- 🇺🇸
Winship Cancer Institute / Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma
- First Posted Date
- 2013-06-10
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT01874054
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Saint Francis Hospital / Bon Secours, Greenville, South Carolina, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2013-02-07
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 92
- Registration Number
- NCT01786096
- Locations
- 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸All Children's Hospital, Saint Petersburg, Florida, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States